Evidence-Based Complementary and Alternative Medicine

Complementary and Alternative Medicine in Cancer Stem Cells


Publishing date
14 Jun 2013
Status
Published
Submission deadline
25 Jan 2013

Lead Editor

1Department of Biochemical Science and Technology, National Chiayi University, Chiayi 600, Taiwan

2Department of Radiation Oncology, Columbia University, New York, NY 10032, USA

3Department of Medical Research and Department of Radiation Oncology, Mackay Memorial Hospital, Taipei 104, Taiwan

4Department of Ophthalmology and Visual Sciences, Vanderbilt University, Nashville, TN 37232, USA


Complementary and Alternative Medicine in Cancer Stem Cells

Description

Cancer stem cells (CSCs) resemble normal stem cells with self-renewal and differentiation characteristics. CSCs have been detected within cancers that may form tumorigenesis from a small subpopulation of cells. CSCs have recently been identified in leukemia and solid tumors, including melanoma, multiple myeloma, brain, breast, colon, ovary, pancreas, and prostate cancers. There is growing evidence indicating that CSCs are principal players to the development of resistance to cancer treatments including chemotherapy and radiotherapy. This is clinically significant since resistant CSCs may lead to relapse and distant metastasis and give rise to new tumors. Emerging data indicates that CSCs and normal stem cells may share cellular pathways regulating proliferation and differentiation. These pathways include, but not limited to, polycomb group transcriptional repressor Bmi-1, Notch, Sonic hedgehog, and Wnt pathways. Therefore, identification of CSC markers, selection and development of unique therapeutics targeting CSCs, and mechanisms regulating of molecular expression of CSCs phenotype which prevent recurrence or metastasis will provide insight to novel intervention strategies for future cancer treatments. We invite experts to contribute original research and review articles that explore aspects of complementary and alternative medicine (CAM) that associated with CSCs in basic research, in translational medicine, and in clinical application for cancer treatment.

The topic will highlight current research, encourage additional research, draw attention to the subject, and ultimately help advance the field of CAM application in CSCs. All the articles need to be related to the area of CAM. Potential topics include, but are not limited to:

  • Screening platform establishment for effective agents acting on CSCs
  • Development of agents modulating CSC signaling pathways
  • Overcoming treatment resistance related to CSCs
  • Influencing of microenvironment on CSCs
  • Targeting therapeutics and accompanying biomarkers on CSCs
  • Translational research on CAM treatment and CSCs
  • Chemical modification, formulation, optimization, and pharmacokinetics/pharmacodynamics of CAM related to management of CSCs
  • Recent advances in drug development from CAM related to CSCs
  • Genetic approaches to personalized medicine related to CAM and CSCs
  • Evaluation of the advantage and disadvantage in CSC aspect of conventional cancer treatment with and without the combination of CAM

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ecam/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/ecam/cstem/ according to the following timetable:

Evidence-Based Complementary and Alternative Medicine
 Journal metrics
See full report
Acceptance rate8%
Submission to final decision164 days
Acceptance to publication28 days
CiteScore3.500
Journal Citation Indicator-
Impact Factor-

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.